Please login to the form below

Not currently logged in
Email:
Password:

The Accenture Award for Company of the Year (>£150m)

Winner

AstraZeneca


Summary of work

Winner:

AstraZeneca is one of the world’s leading pharmaceutical companies, with a major presence in the UK. Its business is focused on providing innovative, effective medicines that make a real difference in important areas of healthcare.

The company’s commitment and contribution to UK healthcare goes far beyond the development of medicines and reflects its shared agenda with other stakeholders.

AstraZeneca’s relationship with the NHS is at the centre of its UK marketing company activities. The NHS is the primary customer for its medicines in the UK and the company engages with NHS staff on many levels on a daily basis. 

Across the organisation, AstraZeneca interacts with healthcare professionals as part of its sales and marketing work, ensuring that clinicians have access to information about products in order to make appropriate prescribing decisions. In addition, the company works closely with the NHS at a national and local level to provide information regarding health economic offerings and value propositions offered to the health service to facilitate decision making and budgetary planning.

AstraZeneca is committed to ensuring that it is aligned with NHS priorities and that it is as engaged with those priorities as possible. In the UK, the company has been transitioning towards a more customer-centric approach to building relationships with stakeholders in the NHS, enabling it to work more collaboratively based on better understanding the needs of customers.

The company has and will continue to evolve business structures, ways of working and customer engagement activities towards being a trusted and valued partner to NHS.

Judges comments

“AZ has been through a fundamental cultural change and completely altered its commercial model with great success. It has piloted a number of new projects and worked hard to connect the UK operating company into Europe and its healthcare systems. Despite stretched resources it has come a long way and really understands the new environment it is working in.”